- 36 次围观
产品图片
货号/SKU
NR-55305
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-55305?? Vector pCMV/R Containing the SARS-Related Coronavirus 2, Spike Glycoprotein Gene, Lineage B.1.351, Beta Variant(Plasmid/Vectors)|SARS-Related Coronavirus 2|Vector pCMV/R Containing the SARS-Related Coronavirus 2, Spike Glycoprotein Gene, Lineage B.1.351, Beta Variant| -20°C or colder|B GrahamAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Vector pCMV/R Containing the SARS-Related Coronavirus 2, Spike Glycoprotein Gene, Lineage B.1.351, Beta Variant, NR-55305.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
NR-55305 expresses the full-length, Beta variant spike (S) glycoprotein, and is intended for producing pseudotyped particles/pseudovirions. NR-55305 is not intended for recombinant protein expression.
The vector for the S glycoprotein gene from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), Wuhan-Hu-1 (GenBank: MN908947) was designed by codon optimizing the full-length S sequence (residues 1 to 1273) for mammalian expression and introducing point mutations found in the B.1.351 lineage, resulting in a spike glycoprotein gene representative of the Beta variant. The spike gene was subcloned into the pCMV/R mammalian expression vector (also referred to as VRC8400). The protein encoded by NR-55305 contains the following point mutations: L18F, D80A, D215G, LAL242-244del, R246I, K417N, E484K, N501Y, D614G and A701V. The kanamycin resistance gene, aph, provides transformant selection through kanamycin resistance in Escherichia coli (E. coli). NR-55305 is also referred to as VRC7597. The resulting size of the plasmid is approximately 8240 base pairs. The complete plasmid sequence and map are provided on the BEI Resources webpage. The plasmid was produced in E. coli and extracted.
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor, allows fusion of the viral and cellular membranes. The S protein is a target for neutralizing antibodies. The Beta variant includes three mutations in the receptor binding domain that may have functional significance: K417N, E484K and N501Y. Structural modeling and mouse studies indicate N501Y increases S glycoprotein binding to ACE2, resulting in increased SARS-CoV-2 virulence.
Each vial contains plasmid DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). The vial should be centrifuged prior to opening. Note: The contents of the vial should be used to replicate the plasmid in E. coli prior to mammalian expression.
NR-55305 expresses the full-length, Beta variant spike (S) glycoprotein, and is intended for producing pseudotyped particles/pseudovirions. NR-55305 is not intended for recombinant protein expression.
The vector for the S glycoprotein gene from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), Wuhan-Hu-1 (GenBank: MN908947) was designed by codon optimizing the full-length S sequence (residues 1 to 1273) for mammalian expression and introducing point mutations found in the B.1.351 lineage, resulting in a spike glycoprotein gene representative of the Beta variant. The spike gene was subcloned into the pCMV/R mammalian expression vector (also referred to as VRC8400). The protein encoded by NR-55305 contains the following point mutations: L18F, D80A, D215G, LAL242-244del, R246I, K417N, E484K, N501Y, D614G and A701V. The kanamycin resistance gene, aph, provides transformant selection through kanamycin resistance in Escherichia coli (E. coli). NR-55305 is also referred to as VRC7597. The resulting size of the plasmid is approximately 8240 base pairs. The complete plasmid sequence and map are provided on the BEI Resources webpage. The plasmid was produced in E. coli and extracted.
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor, allows fusion of the viral and cellular membranes. The S protein is a target for neutralizing antibodies. The Beta variant includes three mutations in the receptor binding domain that may have functional significance: K417N, E484K and N501Y. Structural modeling and mouse studies indicate N501Y increases S glycoprotein binding to ACE2, resulting in increased SARS-CoV-2 virulence.
Each vial contains plasmid DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). The vial should be centrifuged prior to opening. Note: The contents of the vial should be used to replicate the plasmid in E. coli prior to mammalian expression.
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.通过此限制的订单将在发货前发送至NIAID进行批准.
NR-55305表达全长β变体峰值糖蛋白，并且用于产生假型颗粒/假致血管毒性. NR-55305不适用于重组蛋白表达.
来自严重急性呼吸综合征相关冠状病毒2（SARS-COV-2）的S糖蛋白基因的载体（SARS-COV-2），Wuhan-hu-1（Genbank： ）由密码子优化哺乳动物表达的全长S序列（残留物1至1273）设计，并在B.1.351谱系中引入点突变，导致尖峰糖蛋白基因代表β变体.将尖峰基因亚克隆到PCMV / R哺乳动物表达载体中（也称为VRC8400）. NR-55305编码的蛋白质含有以下点突变：L18F，D80A，D215G，LA1242-244DEL，R246I，K417N，E484K，N501Y，D614G和A701V. Kanamycin抵抗基因， APH 通过在大肠杆菌中通过Kanamycin抗性提供转化体选择
Coli（大肠杆菌）. NR-55305也称为VRC7597.得到的质粒尺寸约为8240碱基对.在北部资源网页上提供完整的质粒序列和地图.在 e中制备质粒. Coli 并提取.
S糖蛋白介导与宿主血管紧张素转化酶2（ACE2）的病毒结合.该蛋白质形成三聚体，并且当与宿主受体结合时，允许融合病毒和融合
细胞膜. S蛋白是用于中和抗体的靶标. β变体包括受体结合结构域中的三个突变，其可具有功能意义：K417N，E484K和N501Y.结构建模和小鼠研究表明N501Y增加了糖蛋白与ACE2的结合，导致SARS-COV-2毒力增加.
每个小瓶在Te缓冲液中含有质粒DNA（10mM Tris-HCl，1mM EDTA，pH8.0）.在打开之前应该离心小瓶. 注意：Vial的内容应该用于复制 e中的质粒. Coli 在哺乳动物表达之前.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2024-08-18
2021-12-21
2025-04-23
2024-01-11
2022-04-01
2021-12-21
2022-04-01
2021-12-21
2021-12-21
2021-12-21
2023-12-13
2021-12-21
2019-06-24
2024-01-21
2024-01-21